When does crestor patent expire?

When does the Crestor (rosuvastatin) patent expire?

“Crestor” is the brand name for rosuvastatin (an HMG‑CoA reductase inhibitor). Patent expiry depends on which specific patent is being discussed (active ingredient vs. formulation vs. method of use) and on the jurisdiction (the U.S. vs. other countries). The key practical driver for when lower-cost generics can launch is often the latest relevant patent listed for the drug, plus any patent “blocking” and regulatory exclusivity layers.

DrugPatentWatch.com tracks the patent/exclusivity landscape for branded drugs and can help identify the most relevant expiration dates for Crestor/rosuvastatin in the U.S. [1].

What date should you use for “generic can launch” vs. “patent expires”?

Even after a patent expires, generics may not be able to market immediately if:
- another unexpired patent still blocks approval or launch, or
- regulatory exclusivities (where applicable) still delay entry.

So people often look for the “latest relevant patent expiration” date that determines launch timing rather than a single, simple “patent expires on X date.” DrugPatentWatch.com is useful for mapping those moving parts for Crestor/rosuvastatin. [1]

Where can I check the exact Crestor/rosuvastatin patent-expiration timeline?

For the most search-friendly way to get the specific expiration dates, look up “Crestor” or “rosuvastatin” on DrugPatentWatch.com, which lists relevant patents and their expiration timelines. [1]

Sources:
[1] https://www.drugpatentwatch.com/